These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1694908)

  • 1. Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):868-76. PubMed ID: 1694908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of ketanserin in hypertension and vasospastic disease.
    Wenting GJ; Brouwer RM; vd Meiracker AJ; Man in't Veld AJ; Schalekamp MA
    Acta Cardiol; 1987; 42(5):339-54. PubMed ID: 2827406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
    Seibold JR; Jageneau AH
    Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
    Dormandy JA; Berent A; Downes SJ
    Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
    Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
    Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
    Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
    Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.
    Marasini B; Bassani C
    Br J Clin Pharmacol; 1990 Dec; 30(6):847-51. PubMed ID: 2288831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital blood flow response to body warming, cooling, and rewarming in patients with Raynaud's phenomenon.
    Lau CS; Khan F; Brown R; McCallum P; Belch JJ
    Angiology; 1995 Jan; 46(1):1-10. PubMed ID: 7818151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.
    Wise RA; Wigley FM; White B; Leatherman G; Zhong J; Krasa H; Kambayashi J; Orlandi C; Czerwiec FS
    Arthritis Rheum; 2004 Dec; 50(12):3994-4001. PubMed ID: 15593189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon.
    Khan F; Coffman JD
    Circulation; 1994 Mar; 89(3):1183-8. PubMed ID: 8124805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
    Wise RA; Wigley F
    J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
    Roald OK; Seem E
    Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.
    Bunker CB; Reavley C; O'Shaughnessy DJ; Dowd PM
    Lancet; 1993 Jul; 342(8863):80-3. PubMed ID: 8100913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.